New hope for recurrent brain cancer? early trial targets immune suppression
NCT ID NCT02669173
First seen Feb 25, 2026 · Last updated May 29, 2026 · Updated 14 times
Summary
This early-phase study tested a combination of two drugs (low-dose capecitabine and bevacizumab) in 12 people whose glioblastoma brain tumor had come back or continued growing despite prior treatment. The goal was to see if the drugs could reduce certain immune cells (MDSCs) that help the tumor hide from the body's defenses. The study focused on safety and biological effects, not on curing the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center
Cleveland, Ohio, 44195, United States
Conditions
Explore the condition pages connected to this study.